Triple-negative breast cancer: Distinguishing between basal and nonbasal subtypes

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2302-2310

  Rakha, Emad A ^a,b   Elsheikh, Somaia E ^a,b   Aleskandarany, Muhammed A ^a,b   Habashi, Hany O ^a,c   Green, Andrew R ^a   Powe, Desmond G ^a   El Sayed, Maysa E ^a   Benhasouna, Ahmed ^a   Brunet, Jean Sébastien ^d,e   Akslen, Lars A ^f   Evans, Andy J ^a   Blamey, Roger ^a   Reis Filho, Jorge S ^g   Foulkes, William D ^d   Ellis, Ian O ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MENOUFIA UNIVERSITY   (Egypt)

^c MANSOURA UNIVERSITY   (Egypt)

^d MCGILL UNIVERSITY   (Canada)

^e PHARSIGHT CORPORATION   (Canada)

^f UNIVERSITY OF BERGEN   (Norway)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER SURVIVAL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; EPITHELIAL CELLS; FEMALE; GENES, BRCA1; HUMANS; IMMUNOPHENOTYPING; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 65249104546     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2132     Document Type: Article

References (49)

1. Perou CM, SorlieT, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
2. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-8.
3. SorlieT, Perou CM,Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
4. van de Rijn M, Perou CM,Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-6.
5. Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 2006;59:729-35.
6. +) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-5.
7. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007;50: 434-8.
8. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008; 123:236-40.
9. Nielsen TO, Hsu FD, Jensen K, et al. Immunohisto- chemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
10. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
11. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007;38:197-204.
12. Cheang MC,Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkershas superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368-76.
13. Rouzier R, Perou CM, Symmans WF,et al. Breast can- cer molecular subtypes respond differently to preopera- tive chemotherapy. Clin Cancer Res 2005;11:5678-85.
14. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006;8:R34.
15. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 2007;9:R16.
16. KreikeB,van Kouwenhove M, Horlings H, Weigelt B, Bartelink H, Van de Vijver MJ. Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.
17. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
18. Diaz LK, Cryns VL, Symmans WF, Sneige N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 2007;14:419-30.
19. Hu Z, FanC,OhDS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.
20. Fan C, Oh DS,Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9.
21. Sasa M, Bando Y, Takahashi M, HiroseT, NagaoT. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol 2008;97:30-4.
22. Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008;111:27-44.
23. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple- negative breast cancer. Cancer 2007;109:25-32.
24. Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007; 7:134.
25. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-32.
26. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double- strand break repair. J Clin Oncol 2008;26:3785-90.
27. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phe- notype in breast cancer. J Natl Cancer Inst 2003;95: 1482-5.
28. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction ofBRCA1 statusin patients with breast cancer us- ing estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-80.
29. Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 2008;39:857-65.
30. Putti TC, El-Rehim DM, Rakha EA, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005;18:26-35.
31. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
32. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005;117:248-55.
33. Saunders PTK, Millar MR, Macpherson S, et al. ER β1and ER β2 splice variant (ERβcx/β2) are expressed in distinct cell populations in the adult human testis. J Clin Endo Metab 2002;87:2706-15.
34. Tavassoli FA, Devilee P. World Health Organization classification of tumours. In: Pathology and genetics: tumours of the breast and female genital organs. Lyon: IARC Press; 2003. p. 19-23.
35. Chappuis PO,Kapusta L,Begin LR,et al. Germline BRCA1/2 mutations andp27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 2000;18:4045-52.
36. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
37. Sorlie T, Wang Y, Xiao C, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006;7:127.
38. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10:R65.
39. Collett K, Stefansson IM, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005; 14:1108-12.
40. Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008;26: 3153-8.
41. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506.
42. - phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008;10:R53.
43. Gauthier ML, Berman HK, Miller C, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 2007;12:479-91.
44. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006;25: 5846-53.
45. Shakya R, Szabolcs M, McCarthy E, et al. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heter- odimer in tumor suppression. Proc Natl Acad Sci U S A 2008;105:7040-5.
46. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8.
47. Eerola H, Heinonen M, Heikkila P, et al. Basal cyto- keratinsin breast tumours among BRCA1,BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2008;10:R17.
48. Conforti R, Boulet T, Tomasic G, et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol 2007; 18:1477-83.
49. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer:acritical review. J Clin Oncol2008;26: 2568-81.